Xenon Pharmaceuticals Inc (NASDAQ:XENE) finished Wednesday with an addition of $0.07 to close at $35.10, an upside of 0.20 percent. An average of 634,360 shares of common stock have been traded in the last five days. There was a fall of -$0.74 in the past week, and it reached a new high 14 times over the past 12 months. The last 20 days have seen an average of 393,345 shares traded, while the 50-day average volume stands at 366,858.
XENE stock has decreased by -8.57% in the last month. The company shares reached their 1-month lowest point of $34.67 on 09/25/23. With the stock rallying to its 52-week high on 06/13/23, shares of the company touched a low of $31.79 and a high of $43.75 in 52 weeks. It has reached a new high 9 times so far this year and lost -10.98% or -$4.33 in price. In spite of this, the price is down -19.77% from the 52-week high.
Insider Transactions
XENE stock investors should be aware that Xenon Pharmaceuticals Inc (XENE) stock had its last reported insider trading activity 35 days ago on Aug 24. In this transaction, the insider spent $967,500. Director, PIMSTONE SIMON N., disposed of 31,713 shares at a price of $38.82 on Jun 01. The insider now owns more than $1,231,247 worth of shares. Prior to that, Director PIMSTONE SIMON N. went on to Sale 62,526 shares at $38.70 each on May 31. An amount of $2,420,051 was transacted.
Valuation Metrics
Xenon Pharmaceuticals Inc (XENE) stock’s beta is 1.36. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 17320.50, the price-to-book (PB) ratio at 3.46.
Financial Health
The quick ratio of Xenon Pharmaceuticals Inc for the three months ended June 29 was 19.34, and the current ratio was 19.34, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.02 and a total debt to equity ratio of 0.02 for the quarter ending June 29. Xenon Pharmaceuticals Inc’s EBITDA margin for the year ending June 29 is -1351.70%, while its operating margin for the same period stands at -141010.61%. Its gross profit as reported stood at $138.58 million compared to revenue of $9.43 million.
Earnings Surprise
The company posted a net income of -$47.46 million in the quarter, while revenues of -$41.73 million were grew 34.34%. The analyst consensus anticipated Xenon Pharmaceuticals Inc’s latest quarter earnings to come in at -$0.7 per share, but it turned out to be -$0.72, a -2.90% surprise. For the quarter, EBITDA amounted to -$55.02 million. Shareholders own equity worth $64.15 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Xenon Pharmaceuticals Inc (XENE) price momentum. RSI 9-day as of the close on 27 September was 24.21%, suggesting the stock is oversold, with historical volatility in this time frame at 14.16%.
As of today, XENE’s price is $35.27 -2.06% or -$0.74 from its 5-day moving average. XENE is currently trading -9.00% lower than its 20-day SMA and -15.14% lower than its 100-day SMA. However, the stock’s current price level is -10.12% below the SMA50 and -3.91% below the SMA200.
The stochastic %K and %D were 10.12% and 10.19%, respectively, and the average true range (ATR) was 1.13. With the 14-day stochastic at 9.93% and the average true range at 1.15, the RSI (14) stands at 32.34%. The stock has reached -0.70 on the 9-day MACD Oscillator while the 14-day reading was at -1.21.
Analyst Ratings
Cantor Fitzgerald launched coverage on Xenon Pharmaceuticals Inc (NASDAQ: XENE) in its analyst report released on April 25, 2023. The firm assigned the stock an Overweight rating. The consensus rating for Xenon Pharmaceuticals Inc (XENE) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell XENE, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 15 others rate it as a “buy”.
What is XENE’s price target for the next 12 months?
Analysts predict a range of price targets between $46.00 and $60.00, with a median target of $52.00. Taking a look at these predictions, the average price target given by analysts for Xenon Pharmaceuticals Inc (XENE) stock is $52.33.
